Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts tracking the company's fortunes. That rise was slightly more pronounced than the S 500 index's 2.5% increase.
One of these two impactful publications was issued by Swiss bank UBS analyst Eliana Merle. She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share price target intact.
According to reports, Merle's update was based on surveys with medical professionals indicating that the company's next-generation Journavx pain relief treatment is seeing a notable increase in demand.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
€393.50
0.120%
With 52 Buy predictions and not a single Sell prediction Vertex Pharmaceuticals Inc. is an absolute favorite of our community.
As a result the target price of 496 € shows a positive potential of 26.05% compared to the current price of 393.5 € for Vertex Pharmaceuticals Inc..
